Selenium supplementation in inactive moderate to severe Graves’ orbitopathy patients: a randomized controlled trial
Orbit · 2024
DOI: 10.1080/01676830.2024.2315566 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Orbit, 2024. Verfasst von Panida Potita und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bang…. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Quality of Life, Dietary Supplements, Selenium. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Faculty of Medicine, Chulalongkorn University, Department of ophthalmology, King Chulalongkorn Memorial Hospital.
Abstract (Originalsprache)
PURPOSE: This study was designed to evaluate the effect of selenium supplementation in inactive moderate-severe Graves' orbitopathy (GO) patients. METHODS: This study was a single-center, placebo-controlled, double-masked, randomized trial. Inactive moderate-severe GO participants were randomized to receive six months of 200 micrograms/day of selenium supplementation or placebo. Thorough eye exams, clinical activity score (CAS), Graves' Ophthalmopathy quality of life questionnaire (GO-QOL), and serum selenium level were evaluated at baseline and 6 months after the interventions. The chi-squared or Fisher's exact test was used to compare categorical variables. The t-test and the paired t-test were used to compare continuous variables between two independent samples and two dependent samples, respectively. RESULTS: A total of 25 participants were enrolled, 13 in the selenium group and 12 in the placebo group. Both groups had adequate baseline serum selenium levels at 98.96 ± 15.63 mcg/L and 102.55 ± 17.71 mcg/L, respectively. After 6 months of intervention, the selenium group showed a greater improvement in palpebral aperture (mean difference: -1.4 ± 1.7 mm, p = .04) compared to the placebo group (-0.3 ± 2.7 mm). Notably, 5(41.67%) people in the placebo group developed larger palpebral apertures. Proptosis, ocular motility, and soft tissue signs did not change significantly. GO-QOL and CAS score improvement showed no statistically significant difference between both groups. Minor adverse effects were observed. CONCLUSIONS: Selenium supplementation has a positive effect on eyelid aperture even in inactive moderate-to-severe GO patients with a sufficient baseline selenium level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
- Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
- Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
ORCID-Profile: Vannakorn Pruksakorn
Förderung
- Faculty of Medicine, Chulalongkorn University
- Department of ophthalmology, King Chulalongkorn Memorial Hospital
Zitieren
APA
Potita, P., Pruksakorn, V., Srichomkwun, P., Kingpetch, K., & Saonanon, P. (2024). Selenium supplementation in inactive moderate to severe Graves’ orbitopathy patients: a randomized controlled trial. Orbit. https://doi.org/10.1080/01676830.2024.2315566
Vancouver
Potita P, Pruksakorn V, Srichomkwun P, Kingpetch K, Saonanon P. Selenium supplementation in inactive moderate to severe Graves’ orbitopathy patients: a randomized controlled trial. Orbit. 2024. doi:10.1080/01676830.2024.2315566
BibTeX
@article{Potita2024,
author = {Potita, Panida and Pruksakorn, Vannakorn and Srichomkwun, Panudda and Kingpetch, Kanaungnit and Saonanon, Preamjit},
title = {Selenium supplementation in inactive moderate to severe Graves’ orbitopathy patients: a randomized controlled trial},
journal = {Orbit},
year = {2024},
doi = {10.1080/01676830.2024.2315566}
}
EUVIMED